Clinical trials play a critical role in research and in making discoveries in healthcare. It’s these breakthroughs in science that help people defy the limitation of their disease. This would not be possible without the participation of patients, who ar
The article reveals that fewer than one-quarter of the clinical trials registered at ClinicalTrials.gov have had their results posted in the database within a year of publication, according to two analyses. In one study, it was found that only 165 of 738 trials had met their reporting dead...
智通财经APP获悉，近日，clinicaltrials.gov网站显示，礼来(LLY.US)登记了GLP-1R/GIPR/GCGR三靶点激动剂retatrutide的一项随机、多中心、开放标签的III期临床试验，旨在评估retatrutide相较于司美格鲁肽在二甲双胍联合或不联合钠-葡萄糖共转运体2抑制剂(SGLT2i)治疗血糖控制不佳的2型糖尿病患者中的有效性和安全性。
智通财经APP获悉，2024年8月13日，葛兰素史克(GSK.US)在Clinicaltrials.gov网站上注册了重组RSV疫苗的中国三期临床试验。葛兰素史克的重组RSV疫苗于去年5月获得FDA批准上市，此次注册的中国三期临床为桥接三期，计划入组2600例60岁以上健康人，预计2025年3月完成主要终点随访。该桥接三期临床的主要终点为免疫原性，包括RSV...
智通财经APP获悉,近日,clinicaltrials.gov网站显示,礼来(LLY.US)登记了GLP-1R/GIPR/GCGR三靶点激动剂retatrutide的一项随机、多中心、开放标签的III期临床试验,旨在评估retatrutide相较于司美格鲁肽在二甲双胍联合或不联合钠-葡萄糖共转运体2抑制剂(SGLT2i)治疗血糖控制不佳的2型糖尿病患者中的有效性和安全性。
智通财经APP获悉,近日,clinicaltrials.gov网站显示,礼来(LLY.US)登记了GLP-1R/GIPR/GCGR三靶点激动剂retatrutide的一项随机、多中心、开放标签的III期临床试验,旨在评估retatrutide相较于司美格鲁肽在二甲双胍联合或不联合钠-葡萄糖共转运体2抑制剂(SGLT2i)治疗血糖控制不佳的2型糖尿病患者中的有效性和安全性。
智通财经APP获悉,近日,clinicaltrials.gov网站显示,礼来(LLY.US)登记了GLP-1R/GIPR/GCGR三靶点激动剂retatrutide的一项随机、多中心、开放标签的III期临床试验,旨在评估retatrutide相较于司美格鲁肽在二甲双胍联合或不联合钠-葡萄糖共转运体2抑制剂(SGLT2i)治疗血糖控制不佳的2型糖尿病患者中的有效性和安全性。
ClinicalTrials.gov. Updated August 13, 2019. Accessed March 4, 2021. https://clinicaltrials.gov/ct2/show/NCT02708758 105. Moher D, Pham B, Klassen TP, et al. What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol. 2000...
吉利德(GILD.US)/Arcellx新一代BCMA CAR-T启动三期临床 智通财经APP获悉，2024年5月14日，吉利德(GILD.US)、Arcellx在Clinicaltrials.gov网站上注册了Anitocabtagene Autoleucel治疗复发性或难治性多发性骨髓瘤的三期临床试验。该三期临床将于今年10月启动，计划入组450例复发性或难治性多发性骨髓瘤患者，预计...
Clinical trials registration The eMERGE genomic risk assessment study is a registered, prospective, interventional clinical trial registered with clinicaltrials.gov (Identifier: NCT05277116). The purpose of the study is to determine if providing a GIRA will impact clinical actions taken by providers and...